ITRM Stock Overview
A clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Iterum Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.03 |
| 52 Week High | US$2.39 |
| 52 Week Low | US$0.81 |
| Beta | 2.25 |
| 11 Month Change | 41.96% |
| 3 Month Change | 79.65% |
| 1 Year Change | -2.87% |
| 33 Year Change | -70.44% |
| 5 Year Change | -95.08% |
| Change since IPO | -98.95% |
Recent News & Updates
Recent updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19
Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate
Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
May 06Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Jan 12Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?
Sep 25Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy
Jul 05It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year
Jun 11Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?
May 20Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)
Feb 04Iterum Therapeutics shares slide 13% on raising $10M
Feb 03Iterum Therapeutics rises 39% on RA Capital stake disclosure
Dec 03Iterum Therapeutics files US application for sulopenem in urinary tract infections
Nov 30Iterum Therapeutics EPS beats by $0.45
Nov 16Shareholder Returns
| ITRM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 24.5% | 4.2% | 2.0% |
| 1Y | -2.9% | 13.7% | 32.4% |
Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: ITRM underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ITRM volatility | |
|---|---|
| ITRM Average Weekly Movement | 21.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ITRM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ITRM's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 14 | Corey Fishman | www.iterumtx.com |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc Fundamentals Summary
| ITRM fundamental statistics | |
|---|---|
| Market cap | US$56.41m |
| Earnings (TTM) | -US$30.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs ITRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITRM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.55m |
| Earnings | -US$30.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -195.0% |
How did ITRM perform over the long term?
See historical performance and comparison